In this study, we sought to delineate the effects of a CD38-targeted attenuated IFNα immunocytokine (CD38-AttenukineTM) on tumor cells and/or immune cells, through leveraging different immunocompromised and immunocompetent mouse models. This evidence concerns the gene IFNA2 and neoplasm.